Document Detail


Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites.
MedLine Citation:
PMID:  19454859     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy of vein grafts used in coronary and peripheral artery bypass is limited by excessive hyperplasia and fibrosis that occur early after engraftment. In the present study, we sought to determine whether low-dose spironolactone alleviates maladaptive vein graft arterialization and alters intimal reaction to coronary artery stenting. Yorkshire pigs were randomized to treatment with oral spironolactone 25 mg daily or placebo. All animals underwent right carotid artery interposition grafting using a segment of external jugular vein and, 5 days later, underwent angiography of carotid and coronary arteries. At that time, a bare metal stent was placed in the left anterior descending artery and balloon angioplasty was performed on the circumflex coronary artery. Repeat carotid and coronary angiograms were performed before euthanasia and graft excision at 30 days. Angiography revealed that venous grafts of spironolactone-treated animals had lumen diameters twice the size of controls at 5 days, a finding that persisted at 30 days. However, neointima and total vessel wall areas also were 2- to 3-fold greater in spironolactone-treated animals, and there were no differences in vessel wall layer thicknesses or collagen and elastin densities. In the coronary circulation, there were no differences between treatment groups in any vessel wall parameters in either stented or unstented vessels. Taken together, these observations suggest that low-dose spironolactone may exert a novel protective effect on remodeling in venous arterial grafts that does not depend on the reduction of hyperplastic changes but may involve dilatation of the vessel wall.
Authors:
Matthew D Bacchetta; Arash Salemi; Federico Milla; Mun K Hong; Fermin Tio; Ying Zhou; Rong Chen; Edward Southard; Leonard Y Lee; Charles A Mack; Karl H Krieger; O Wayne Isom; Wilson Ko; Jeffrey S Borer; Daniel F Catanzaro
Related Documents :
12400759 - Use of radial artery graft reduces the morbidity of coronary artery bypass graft surger...
12354699 - First clinical results with a new mechanical connector for distal coronary artery anast...
7798499 - Internal thoracic artery grafts: 20-year clinical follow-up.
8530199 - Evaluation of cryopreserved arteries as alternative small vessel prostheses.
11525539 - Stent graft repair for rupture of the subclavian artery secondary to infection of a sub...
21519219 - Ideal antiplatelet therapy for coronary artery disease: focus on adenosine diphosphate ...
8296659 - Pooled intravenous immunoglobulin in the management of systemic vasculitis.
21406189 - Circulating nampt and rbp4 levels in patients with carotid stenosis undergoing carotid ...
11235689 - Successful retrieval and function of lungs from non-heart-beating donors.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of therapeutics     Volume:  16     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:    2009 May-Jun
Date Detail:
Created Date:  2009-05-20     Completed Date:  2009-07-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  204-14     Citation Subset:  IM    
Affiliation:
Department of Cardiothoracic Surgery, Weill Cornell Medical College, Cornell University, New York, NY 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary*
Angiotensin II Type 1 Receptor Blockers / pharmacology
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Animals
Carotid Arteries / radiography,  surgery*
Coronary Angiography
Coronary Vessels / pathology
Jugular Veins / transplantation*
Spironolactone / therapeutic use*
Stents
Swine
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 52-01-7/Spironolactone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset i...
Next Document:  Influence of laropiprant, a selective prostaglandin d2 receptor 1 antagonist, on the pharmacokinetic...